The therapeutic effective dose was found to be 0.25 mg/kg. This new preparation of 8-MOP proved to be well tolerated by the patients, causing no epigastric discomfort, nausea, or vomiting, overcoming the biggest obstacle of oral 8-MOP therapy. It was also well tolerated by patients known to be sensitive to oral and/or topical 8-MOP therapy.
No takes yet. Share an insight, caveat, or question.
El‐Mofty et al. (1994) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: